SMARCA4 deficiency is associated with poor prognosis in non-small cell lung cancer (NSCLC). Here the authors report that loss of SMARCA4 in NSCLC cells is associated with resistance to ferroptosis, mediated via inhibition of ALDH16A1 expression and thioredoxin degradation.